The complement system in preeclampsia: a review of its activation and endothelial injury in the triad of COVID-19 infection and HIV-associated preeclampsia

키워드

참고문헌 (139)

1. Merle NS, "Complement system part I-molecular mechanisms of activation and regulation", Front Immunol, 6, pp.262~ (2015)
2. Lokki AI, "Complement activation and regulation in preeclamptic placenta", Front Immunol, 5, pp.312~ (2014)
3. "Global HIV & AIDS statistics-2020 fact sheet" (2020)[URL]
4. Maartens G, "HIV infection : epidemiology, pathogenesis, treatment, and prevention", Lancet, 384, pp.258~271 (2014)
5. Kalumba VM, "Is the prevalence of pre-eclampsia affected by HIV", AIDS? A retrospective case-control study, 2013, pp.24, 24~27
6. Rodriguez-Morales AJ, "History is repeating itself : probable zoonotic spillover as the cause of the 2019 novel coronavirus epidemic", Infez Med, 28, pp.3~5 (2020)
7. Pal M, "Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) : an update", Cureus, 12, pp.e7423~ (2020)
8. Gavriilaki E, "Severe COVID-19 infection and thrombotic microangiopathy : success does not come easily", Br J Haematol, 189, pp.e227~30 (2020)
9. Java A, "The complement system in COVID-19 : friend and foe?", JCI Insight, 5, pp.e140711~ (2020)
10. Risitano AM, "Complement as a target in COVID-19?", Nat Rev Immunol, 20, pp.343~344 (2020)
11. Vitiello A, "Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19positive patients by acting on complement cascade", Hum Immunol, 82, pp.264~269 (2021)
12. Gathiram P, "Pre-eclampsia : its pathogenesis and pathophysiolgy", Cardiovasc J Afr, 27, pp.71~78 (2016)
13. He YD, "Normal range of complement components during pregnancy : a prospective study", Am J Reprod Immunol, 83, pp.e13202~ (2020)
14. Shen B, "Proteomic and metabolomic characterization of COVID-19patient sera", Cell, 182, pp.59~72 (2020)
15. Clarke W, "Contemporary practice in clinical chemistry" (2020), Academic Press
16. Noris M, "Overview of complement activation and regulation", Semin Nephrol, 33, pp.479~492 (2013)
17. McDonald CR, "Complement activation in placental malaria", Front Microbiol, 6, pp.1460~ (2015)
18. Regal JF, "The complement system and adverse pregnancy outcomes", Mol Immunol, 67, pp.56~70 (2015)
19. Conroy AL, "Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV", Am J Obstet Gynecol, 217, pp.684~ (2017)
20. Schmidt CQ, "Protection of host cells by complement regulators", Immunol Rev, 274, pp.152~171 (2016)
21. Beltrame MH, "The lectin pathway of complement and rheumatic heart disease", Front Pediatr, 2, pp.148~ (2015)
22. Wang W, "Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels : a population-based study", BMC Pregnancy Childbirth, 21, pp.364~ (2021)
23. Collier AY, "Maternal mortality in the United States : updates on trends, causes, and solutions", Neoreviews, 20, pp.e561~74 (2019)
24. Rana S, "Preeclampsia : pathophysiology, challenges, and perspectives", Circ Res, 124, pp.1094~1112 (2019)
25. Brown MA, "Hypertensive disorders of pregnancy : ISSHP classification, diagnosis, and management recommendations for international practice", Hypertension, 72, pp.24~43 (2018)
26. Phipps E, "Preeclampsia : updates in pathogenesis, definitions, and guidelines", Clin J Am Soc Nephrol, 11, pp.1102~1113 (2016)
27. Staff AC, "Redefining preeclampsia using placenta-derived biomarkers", Hypertension, 61, pp.932~942 (2013)
28. McNally R, "Elucidating the pathogenesis of pre-eclampsia using in vitro models of spiral uterine artery remodelling", Curr Hypertens Rep, 19, pp.93~ (2017)
29. Li H, "Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model", Sci Rep, 5, pp.15271~ (2015)
30. Tomimatsu T, "Pathophysiology of preeclampsia : an angiogenic imbalance and long-lasting systemic vascular dysfunction", Hypertens Res, 40, pp.305~310 (2017)
31. "Mid-year population estimates 2021" (2021)[URL]
32. Reshi P, "Human immunodeficiency virus and pregnancy", Arch Gynecol Obstet, 281, pp.781~792 (2010)
33. Siegfried N, "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection", Cochrane Database Syst Rev, pp.CD003510~ (2011)
34. Fourie C, "Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa?", Cardiovasc J Afr, 22, pp.134~140 (2011)
35. Govender N, "Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia", Cardiovasc J Afr, 24, pp.174~179 (2013)
36. Landi B, "HIV infection in pregnancy and the risk of gestational hypertension and preeclampsia", WJCD, 4, pp.11~ (2014)
37. Kline ER, "The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction", J Investig Med, 56, pp.752~769 (2008)
38. "WHO coronavirus (COVID-19) dashboard" (2023)[URL]
39. Gheblawi M, "Angiotensin-converting enzyme 2 : SARS-CoV-2 receptor and regulator of the reninangiotensin system : celebrating the 20th anniversary of the discovery of ACE2", Circ Res, 126, pp.1456~1474 (2020)
40. Wan Y, "Receptor recognition by the novel coronavirus from Wuhan : an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 94, pp.e00127-20~ (2020)
41. Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19) : a review", JAMA, 324, pp.782~793 (2020)
42. Harapan H, "Coronavirus disease 2019(COVID-19) : a literature review", J Infect Public Health, 13, pp.667~673 (2020)
43. Harsh Goel, "A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases", Obstetrics & Gynecology Science, 64(2), pp.174~189 (2021), 대한산부인과학회[DOI]
44. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
45. Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China", Intensive Care Med, 46, pp.846~848 (2020)
46. Huang S, "Elevated C-reactive protein and complement C3 levels are associated with preterm birth : a nested case-control study in Chinese women", BMC Pregnancy Childbirth, 20, pp.131~ (2020)
47. Vardhana SA, "The many faces of the anti-COVID immune response", J Exp Med, 217, pp.e20200678~ (2020)
48. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
49. Varga Z, "Endothelial cell infection and endotheliitis in COVID-19", Lancet, 395, pp.1417~1418 (2020)
50. "Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The mount sinai COVID-19 autopsy experience" (2020)[URL]
51. Su H, "Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China", Kidney Int, 98, pp.219~227 (2020)
52. Magro C, "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection : a report of five cases", Transl Res, 220, pp.1~13 (2020)
53. Panigada M, "Hypercoagulability of COVID-19 patients in intensive care unit : a report of thromboelastography findings and other parameters of hemostasis", J Thromb Haemost, 18, pp.1738~1742 (2020)
54. Escher R, "Severe COVID-19 infection associated with endothelial activation", Thromb Res, 190, pp.62~ (2020)
55. Chatterjee P, "The 2019 novel coronavirus disease(COVID-19)pandemic : a review of the current evidence", Indian J Med Res, 151, pp.147~159 (2020)
56. Wastnedge EAN, "Pregnancy and COVID-19", Physiol Rev, 101, pp.303~318 (2021)
57. Enninga EA, "Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period", Am J Reprod Immuno, 73, pp.251~262 (2015)
58. Mor G, "The unique immunological and microbial aspects of pregnancy", Nat Rev Immunol, 17, pp.469~482 (2017)
59. Cugno M, "Complement activation in patients with COVID-19 : a novel therapeutic target", J Allergy Clin Immunol, 146, pp.215~217 (2020)
60. Breslin N, "Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women : two weeks of confirmed presentations to an affiliated pair of New York City hospitals", Am J Obstet Gynecol MFM, 2, pp.100118~ (2020)
61. Mendoza M, "Pre-eclampsia-like syndrome induced by severe COVID-19 : a prospective observational study", BJOG, 127, pp.1374~1380 (2020)
62. Shanes ED, "Placental pathology in COVID-19", Am J Clin Pathol, 154, pp.23~32 (2020)
63. Estrada-Chiroque LM, "Clinical characteristics and maternal perinatal outcome in women with a confirmed diagnosis of COVID-19 in a hospital in Peru. Retrospective cohort study", Rev Colomb Obstet Ginecol, 73, pp.28~38 (2022)
64. Coronado-Arroyo JC, "Is COVID-19a risk factor for severe preeclampsia? Hospital experience in a developing country", Eur J Obstet Gynecol Reprod Biol, 256, pp.502~503 (2021)
65. Todros T, "COVID-19 infection : ACE2, pregnancy and preeclampsia", Eur J Obstet Gynecol Reprod Biol, 253, pp.330~ (2020)
66. Ahlberg M, "Association of SARS-CoV-2test status and pregnancy outcomes", JAMA, 324, pp.1782~1785 (2020)
67. Wei SQ, "Increased pregnancy problems with COVID-19-metaanalysis and letter to editor-April 2021", CMAJ, 193, pp.E540~8 (2021)
68. Brosnihan KB, "Enhanced expression of ang-(1-7)during pregnancy", Braz J Med Biol Res, 37, pp.1255~1262 (2004)
69. West CA, "The enigma of continual plasma volume expansion in pregnancy : critical role of the renin-angiotensin-aldosterone system", Am J Physiol Renal Physiol, 311, pp.F1125~34 (2016)
70. Merrill DC, "Angiotensin-(1-7)in normal and preeclamptic pregnancy", Endocrine, 18, pp.239~245 (2002)
71. Glowacka I, "Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63", J Virol, 84, pp.1198~1205 (2010)
72. Klok FA, "Incidence of thrombotic complications in critically ill ICU patients with COVID-19", Thromb Res, 191, pp.145~147 (2020)
73. Inciardi RM, "Coronavirus 2019 disease(COVID-19), systemic inflammation, and cardiovascular disease", J Am Heart Assoc, 9, pp.e017756~ (2020)
74. Garovic VD, "Hypertension in pregnancy : an emerging risk factor for cardiovascular disease", Nat Clin Pract Nephrol, 3, pp.613~622 (2007)
75. Alrahmani L, "The complement alternative pathway and preeclampsia", Curr Hypertens Rep, 20, pp.40~ (2018)
76. Dusse LM, "Pre-eclampsia : relationship between coagulation, fibrinolysis and inflammation", Clin Chim Acta, 412, pp.17~21 (2011)
77. Kucukgoz Gulec U, "An analysis of C-reactive protein, procalcitonin, and Ddimer in pre-eclamptic patients", Am J Reprod Immunol, 68, pp.331~337 (2012)
78. Bozkurt M, "Troponin I and D-dimer levels in preeclampsia and eclampsia : prospective study", Clin Exp Obstet Gynecol, 42, pp.26~31 (2015)
79. Gutiérrez García I, "D-dimer during pregnancy : establishing trimester-specific reference intervals", Scand J Clin Lab Invest, 78, pp.439~442 (2018)
80. Posch W, "HIVhost interactions", pp.100~115 (2011), InTechOpen
81. Hladik F, "Setting the stage : host invasion by HIV", Nat Rev Immunol, 8, pp.447~457 (2008)
82. de Jong MA, "Langerhans cells in innate defense against pathogens", Trends Immunol, 31, pp.452~459 (2010)
83. Roberts L, "Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression", AIDS, 24, pp.819~831 (2010)
84. Ricklin D, "Complement in immune and inflammatory disorders : pathophysiological mechanisms", J Immunol, 190, pp.3831~3838 (2013)
85. Alqudah MA, "HIV-1 strategies to overcome the immune system by evading and invading innate immune system", HIV AIDS Rev, 15, pp.1~12 (2016)
86. Popko K, "Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects", Eur J Med Res, 15(Suppl 2), pp.120~122 (2010)
87. Pierik E, "Dysregulation of complement activation and placental dysfunction : a potential target to treat preeclampsia?", Front Immunol, 10, pp.3098~ (2020)
88. Hsu P, "Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia", Front Immunol, 5, pp.125~ (2014)
89. Perez-Sepulveda A, "Innate immune system and preeclampsia", Front Immunol, 5, pp.224~ (2014)
90. Ito Y, "Increased expression of perforin, granzyme B, and C5b-9 in villitis of unknown etiology", Placenta, 36, pp.531~537 (2015)
91. Banadakoppa M, "Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells", Am J Reprod Immunol, 80, pp.e13033~ (2018)
92. Denny KJ, "Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia", J Reprod Immunol, 97, pp.211~216 (2013)
93. Rampersad R, "The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro", Placenta, 29, pp.855~861 (2008)
94. Pooja Wadhwani, "A study to compare maternal and perinatal outcome in early vs. late onset preeclampsia", Obstetrics & Gynecology Science, 63(3), pp.270~277 (2020), 대한산부인과학회[DOI]
95. Morgan BP, "The membrane attack complex as an inflammatory trigger", Immunobiology, 221, pp.747~751 (2016)
96. Derzsy Z, "Activation of the complement system in normal pregnancy and preeclampsia", Mol Immunol, 47, pp.1500~1506 (2010)
97. Girardi G, "Complement activation, a threat to pregnancy", Semin Immunopathol, 40, pp.103~111 (2018)
98. Regal JF, "The complement system and preeclampsia", Curr Hypertens Rep, 19, pp.87~ (2017)
99. Gilbert JS, "Complement activation in pregnancy : too much of a good thing?", Hypertension, 60, pp.1114~1116 (2012)
100. Yonekura Collier AR, "Placental sFLT1is associated with complement activation and syncytiotrophoblast damage in preeclampsia", Hypertens Pregnancy, 38, pp.193~199 (2019)
101. Lynch AM, "Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications", Placenta, 31, pp.561~567 (2010)
102. Burwick RM, "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome", Am J Obstet Gynecol, 226, pp.S1059~70 (2022)
103. Girardi G, "Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction", J Exp Med, 203, pp.2165~2175 (2006)
104. Valencia CM, "67 : improved diagnosis of preeclampsia with severe features and end organ injury using complement activation measurement in urine and plasma", Am J Obstet Gynecol, 218, pp.S49~50 (2018)
105. Lynch AM, "The relationship of circulating proteins in early pregnancy with preterm birth", Am J Obstet Gynecol, 214, pp.517~ (2016)
106. Gralinski LE, "Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis", mBio, 9, pp.e01753-18~ (2018)
107. "Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation" (2020)[URL]
108. Rambaldi A, "Endothelial injury and thrombotic microangiopathy in COVID-19 : treatment with the lectin-pathway inhibitor narsoplimab", Immunobiology, 225, pp.152001~ (2020)
109. Li Y, "Urine proteome of COVID-19 patients", Urine(Amst), 2, pp.1~8 (2020)
110. Diao B, "Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection", Nat Commun, 12, pp.2506~ (2021)
111. Magro G, "Cytokine storm: is it the only major death factor in COVID-19 patients? Coagulation role", Med Hypotheses, 142, pp.109829~ (2020)
112. "Identification of immune complement function as a determinant of adverse SARS-CoV-2 infection outcome" (2020)[URL]
113. Liszewski MK, "Complement dysregulation and disease : insights from contemporary genetics", Annu Rev Pathol, 12, pp.25~52 (2017)
114. Ghai R, "C1q and its growing family", Immunobiology, 212, pp.253~266 (2007)
115. Madhukaran SP, "Role of collectins and complement protein C1q in pregnancy and parturition", Immunobiology, 221, pp.1273~1288 (2016)
116. Clarke EV, "Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation", J Leukoc Biol, 97, pp.147~160 (2015)
117. Hoffmann M, "A multibasic cleavage site in the spike protein of SARS-CoV-2is essential for infection of human lung cells", Mol Cell, 78, pp.779~784 (2020)
118. Yang W, "Maternal hypertensive disorders in pregnancy and risk of hypoxic-ischemia encephalopathy", J Matern Fetal Neonatal Med, 34, pp.1754~1762 (2021)
119. Weetman AP, "Immunity, thyroid function and pregnancy : molecular mechanisms", Nat Rev Endocrinol, 6, pp.311~318 (2010)
120. Pazos M, "The influence of pregnancy on systemic immunity", Immunol Res, 54, pp.254~261 (2012)
121. Picone O, "Determination of rubella virus-specific humoral and cell-mediated immunity in pregnant women with negative or equivocal rubella-specific IgG in routine screening", J Clin Virol, 112, pp.27~33 (2019)
122. Lokki AI, "The immunogenetic conundrum of preeclampsia", Front Immunol, 9, pp.2630~ (2018)
123. Teirilä L, "Regulation of the complement system and immunological tolerance in pregnancy", Semin Immunol, 45, pp.101337~ (2019)
124. Tsafaras GP, "Advantages and limitations of the neonatal immune system", Front Pediatr, 8, pp.5~ (2020)
125. Ferrer-Oliveras R, "Immunological and physiopathological approach of COVID-19 in pregnancy", Arch Gynecol Obstet, 304, pp.39~57 (2021)
126. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
127. Muyayalo KP, "COVID-19 and Treg", Th17 imbalance : potential relationship to pregnancy outcomes, 2020, pp.84, e13304~
128. Yu Q, "The good and evil of complement activation in HIV-1 infection", Cell Mol Immunol, 7, pp.334~340 (2010)
129. Burwick RM, "Urinary excretion of C5b-9 in severe preeclampsia : tipping the balance of complement activation in pregnancy", Hypertension, 62, pp.1040~1045 (2013)
130. Pillay Y, "The role of the complement system in HIV infection and preeclampsia", Inflamm Res, 68, pp.459~469 (2019)
131. Eisen S, "Mannose-binding lectin in HIV infection", Future Virol, 3, pp.225~233 (2008)
132. Kacani L, "C5a and C5a(desArg)enhance the susceptibility of monocyte-derived macrophages to HIV infection", J Immunol, 166, pp.3410~3415 (2001)
133. Naicker T, "HIV associated preeclampsia : a multifactorial appraisal", Int J Mol Sci, 22, pp.9157~ (2021)
134. Lannaman K, "Fetal death : an extreme manifestation of maternal anti-fetal rejection", J Perinat Med, 45, pp.851~868 (2017)
135. Bulla R, "The complement system at the embryo implantation site : friend or foe?", Front Immunol, 3, pp.55~ (2012)
136. Singh J, "Role of complement component C1q in the onset of preeclampsia in mice", Hypertension, 58, pp.716~724 (2011)
137. Lynch AM, "Complement activation fragment Bb in early pregnancy and spontaneous preterm birth", Am J Obstet Gynecol, 199, pp.354~ (2008)
138. Burwick RM, "Terminal complement activation in preeclampsia", Obstet Gynecol, 132, pp.1477~1485 (2018)
139. Lillegard KE, "Complement activation is critical for placental ischemia-induced hypertension in the rat", Mol Immunol, 56, pp.91~97 (2013)

관련 논문AI추천